Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.
This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zone
Login to unlock117characters for free
Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.